SUBSCRIBE
SUBSCRIBE

AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
1 North Waukegan Road
North Chicago, IL 60064
Tel: 1-800-255-5162
Visit website
Email Us
Stock Symbol: ABBV
Stock Exchange: NYSE
  • Featured Employer
NEWS
Deals
Amid Positive Phase III RA News, Galapagos Announces $300 Million Score from U.S. IPO
Belgium-based Galapagos NV snagged $300 million following its U.S. public offering of new ordinary shares in the form of American Depositary Shares.
September 13, 2018
 · 
2 min read
 · 
Alex Keown
Gilead's $12B Bet Pays Off in Two Months After the
Business
With Phase II Win for Ankylosing Spondylitis, Gilead and Galapagos’ Filgotinib Inches Toward Approval
Gilead Sciences and its partner Galapagos NV announced results from its Phase II TORTUGA clinical trial of filgotinib, a selective JAK1 inhibitor, in adults with moderately to severely active ankylosing spondylitis (AS).
September 6, 2018
 · 
3 min read
 · 
Mark Terry
Pictured: Office building science collage
Job Trends
The Top 12 Biopharma Companies Hiring Now
Despite the changing landscape in biopharma, many companies are still recruiting. If you’re looking to make a career change, here are 12 biopharma companies hiring on BioSpace now.
September 5, 2018
 · 
1 min read
 · 
Editorial Staff
Business
J&J Tops Drucker Institute’s Management Top 250
Each year, Peter Drucker’s Drucker Institute generates its Management Top 250, evaluating companies based on what it calls five dimensions of corporate performance. Those five dimensions are Customer Satisfaction, Employee Engagement and Development, Innovation, Social Responsibility and Financial Strength.
September 4, 2018
 · 
2 min read
 · 
Mark Terry
Drug Development
AbbVie’s Imbruvica and Rituxan Combo Snags FDA Approval for Rare Blood Disease
Shares of AbbVie are inching up this morning after the company announced it had secured regulatory approval for Imbruvica as a treatment for patients with a rare blood disease.
August 27, 2018
 · 
2 min read
 · 
Alex Keown
Business
Biotech Movers and Shakers Aug. 27
Who made a splash in the biotech world this week? Here are some notable people.
August 24, 2018
 · 
3 min read
 · 
Alex Keown
Business
AbbVie Exercises Option to Develop Argenx Immuno-Oncology Compound
Chicago-based AbbVie has exercised its exclusive license option to develop and commercialize Belgium-based Argenx’s ARGX-115. The compound is an antibody that targets novel immuno-oncology target glycoprotein A repetitions predominant (GARP).
August 22, 2018
 · 
2 min read
 · 
Mark Terry
What Brent Saunders Thinks About a Possible Allerg
BioCapital
FDA Rejects Allergan’s Uterine Fibroid Treatment Following EMA Concerns Over Liver Damage
The U.S. Food and Drug Administration rejected Allergan’s New Drug Application for (ulipristal acetate).
August 22, 2018
 · 
3 min read
 · 
Alex Keown
BioMidwest
AbbVie Donates $100 Million to Ronald McDonald House Charities
Illinois-based AbbVie stepped up to the plate and delivered when it came to supporting the families of children battling serious illnesses who require extended hospitalization.
August 21, 2018
 · 
2 min read
 · 
Alex Keown
Load More
JOBS
View All Jobs at AbbVie
IN THE PRESS
BioMidwest
AbbVie Partnering with Global Authorities to Determine Efficacy of HIV Drug in Treating COVID-19
March 9, 2020
 · 
2 min read
Genetown
Enanta’s HCV Collaboration Partner AbbVie Receives Marketing Authorization from European Commission to Shorten MAVIRET® (glecaprevir/pibrentasvir) Duration to Eight Weeks for Treatment-Naïve Genotype 3 HCV Patients with Compensated Cirrhosis
March 6, 2020
 · 
8 min read
BioMidwest
European Commission Grants AbbVie Marketing Authorization Shortening MAVIRET® (glecaprevir/pibrentasvir) Treatment Duration to Eight Weeks for Treatment-Naïve Chronic HCV Patients with Genotype 3 and Compensated Cirrhosis
March 6, 2020
 · 
8 min read
BioMidwest
AbbVie and Allergan Receive Final European Approval to Close Pending Transaction
March 3, 2020
 · 
8 min read
Drug Development
AbbVie Provides Update from Phase 3 Study Evaluating VENCLEXTA® (venetoclax) in Combination with Low-Dose Cytarabine in Newly-Diagnosed Patients with Acute Myeloid Leukemia (AML)
February 28, 2020
 · 
14 min read
Deals
AbbVie Announces Extension of Expiration Date for Exchange Offers for Allergan Notes to March 13, 2020
February 24, 2020
 · 
9 min read
Deals
AbbVie Declares Quarterly Dividend payable on May 15, 2020
February 20, 2020
 · 
1 min read
BioMidwest
AbbVie to Present at the Cowen 40th Annual Health Care Conference
February 19, 2020
 · 
2 min read
BioMidwest
AbbVie to Present at the SVB Leerink 9th Annual Global Healthcare Conference
February 11, 2020
 · 
2 min read
Business
AbbVie Reports Full-Year and Fourth-Quarter 2019 Financial Results
February 7, 2020
 · 
32 min read
Load More